Sacramento, CA Clinical Trials Report — May 2026

For Sacramento residents considering participation in clinical research, May 2026 offers important opportunities, particularly for those looking to act quickly before enrollment windows close. Currently, 42 clinical trials in Sacramento are slated to conclude within the next 90 days, making prompt action essential for interested individuals.

Among these rapidly closing studies, 8 are still actively seeking healthy volunteers, offering a chance to contribute to medical advancements without requiring a specific health condition. This provides a valuable opportunity for those eager to support research efforts before these trials reach their enrollment capacity.

Urgent Opportunities in Key Health Areas

Patients managing specific health conditions also have limited time to join research. Trials focused on various cancers, neurological conditions, and dermatological issues are among those with impending deadlines. Conditions with trials closing soon include:

• Scarring (2 trials)
• Stage IV lung cancer AJCC V8 (2 trials)
• Advanced malignant solid neoplasm (1 trial)
• Advanced renal cell carcinoma (1 trial)
• Advanced triple-negative breast carcinoma (1 trial)
• Age-related macular degeneration (1 trial)
• Alzheimer disease (1 trial)
• Alopecia areata (1 trial)
• Anatomic stage III breast cancer AJCC V8 (1 trial)
• Anatomic stage IV breast cancer (AJCC) V8 (1 trial)

New Research Horizons in Sacramento

This month, Sacramento saw the opening of 6 new clinical trials, an increase from the 4 trials that launched in April 2026. This brings the total number of actively recruiting clinical trials in Sacramento, CA, to 556 across 213 research facilities, highlighting the city's active role in medical research.

May brings several notable new trials to Sacramento, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Eli Lilly and Company is sponsoring a notable Phase 3 study, NCT07602582, "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)." This trial aims for 550 participants to determine if individuals who previously took donanemab for Alzheimer's disease continue to receive clinical benefit with annual doses.
• Apollo Therapeutics Ltd is initiating a Phase 2b study, NCT07599813, "A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis." This randomized, double-blind, placebo-controlled study seeks 280 participants to evaluate a new treatment for atopic dermatitis.
• The University of California, Davis is sponsoring NCT07580183, "Spatial Scene Recognition Memory in Epilepsy Surgery," an observational study involving 620 participants. This research investigates the anatomical and physiological basis of spatial scene recognition memory in patients with temporal lobe epilepsy and lesions.
• The Duchenne Registry is leading NCT07609394, "Duchenne Electronic Health Record Study," an observational study aiming for 2,500 participants. This study will collect long-term data from patients with dystrophinopathy, including Duchenne, Becker, and female carriers, through electronic health record transfers.
• PICO IV, Inc. is sponsoring NCT07609069, "Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform," an observational study with 625 participants. This study will evaluate the kinetic safety and tolerability of an investigational intravenous micellar delivery platform by abstracting medical records.

New trials this month are exploring a range of conditions, with a focus on dermatological and muscular disorders. Conditions for new trials include atopic dermatitis (2 trials), atopic (1 trial), Becker muscular dystrophy (1 trial), dementia (1 trial), and Duchenne muscular dystrophy (DMD) (1 trial). Drug trials account for the largest share of new studies, with 4 new drug trials, alongside behavioral, device, diagnostic test, and other types of studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 6 new trials launched this month, 1 is actively seeking healthy volunteers. Across Sacramento, a total of 47 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Sacramento's Leading Research Facilities

Sacramento is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of California Davis Comprehensive Cancer Center (103 trials)
• Mercy Cancer Center - Sacramento (44 trials)
• Sutter Medical Center Sacramento (39 trials)
• Kaiser Permanente-South Sacramento (35 trials)
• Kaiser Permanente Downtown Commons (34 trials)
• UC Davis Medical Center (29 trials)
• University of California, Davis (29 trials)
• UC Davis Health (18 trials)
• University of California Davis (18 trials)
• South Sacramento Cancer Center (16 trials)

These institutions, particularly those affiliated with UC Davis and Kaiser Permanente, offer a broad spectrum of research, from oncology at the UC Davis Comprehensive Cancer Center and Mercy Cancer Center, to diverse medical fields across the various UC Davis and Kaiser Permanente sites.

Broadening Your Search: Nearby Options in California

While Sacramento offers a robust array of clinical trial opportunities, individuals may also find options in other major cities across California. Cities with active trials include Los Angeles (31 trials), San Francisco (27 trials), Duarte (17 trials), Palo Alto (12 trials), Irvine (11 trials), San Diego (11 trials), La Jolla (8 trials), and Stanford (7 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 6 new trials launched this month, 5 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children. Academic institutions, notably the University of California, Davis, continue to play a vital role in Sacramento's research ecosystem, alongside industry sponsors like Eli Lilly and Company and Apollo Therapeutics Ltd, who are driving significant research efforts.

As we move through May, Sacramento's active research community will continue to contribute to medical innovation, offering diverse opportunities for individuals to advance healthcare for all.